I
Ingemar Ernberg
Researcher at Karolinska Institutet
Publications - 234
Citations - 11898
Ingemar Ernberg is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Epstein–Barr virus & Virus. The author has an hindex of 56, co-authored 227 publications receiving 11074 citations. Previous affiliations of Ingemar Ernberg include Karolinska University Hospital & University of Innsbruck.
Papers
More filters
Journal ArticleDOI
Gene expression perturbation in vitro--a growing case for three-dimensional (3D) culture systems.
TL;DR: How cell lines adapt to in vitro environments, to what degree they express markers of their tissues of origins and how cells grown in three-dimensional (3D) cultures may have more physiological interactions with neighbouring cells and extracellular matrix are reviewed.
Journal ArticleDOI
Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective
TL;DR: It is argued that cancer cells are trapped in abnormal attractors and this concept is discussed in the light of recent ideas in cancer biology, including cancer genomics and cancer stem cells, as well as the implications for differentiation therapy.
Journal ArticleDOI
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.
Robin Fåhraeus,Hu Li Fu,Ingemar Ernberg,Jurgen Finke,Martin Rowe,George Klein,Kerstin I. Falk,Ethel Nilsson,M. Yadav,Philippe Busson,Thomas Tursz,Bengt Kallin +11 more
TL;DR: Investigation of immunoblotting in nasopharyngeal carcinoma biopsies and normal tissue specimens from the head and neck region suggests that expression of the EBV genome is regulated in a tissue‐specific fashion.
Journal ArticleDOI
Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Åsa Gustafsson,Victor Levitsky,Jie Zhi Zou,Teresa Frisan,Tina Dalianis,Per Ljungman,Olle Ringdén,Jacek Winiarski,Ingemar Ernberg,Maria G. Masucci +9 more
TL;DR: The results suggest that prophylactic administration of EBV-CTLs early after BMT appears to provide the most effective protection against the development ofEBV-associated lymphoproliferative disease.
Journal ArticleDOI
Caring for patients with cancer in the COVID-19 era.
Joris van de Haar,L.R. Hoes,Charlotte E. Coles,Kenneth Seamon,Stefan Fröhling,Dirk Jäger,Franco Valenza,Filippo de Braud,Luigi De Petris,Luigi De Petris,Jonas Bergh,Jonas Bergh,Ingemar Ernberg,Benjamin Besse,Fabrice Barlesi,Fabrice Barlesi,Elena Garralda,Alejandro Piris-Giménez,Michael Baumann,Giovanni Apolone,Jean-Charles Soria,Josep Tabernero,Carlos Caldas,Emile E. Voest +23 more
TL;DR: How the seven comprehensive cancer centers of Cancer Core Europe have organized their healthcare systems at an unprecedented scale and pace to make their operations ‘pandemic proof’ is reported.